uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intravenous iron alone resolves anemia in patients with functional iron deficiency and lymphoid malignancies undergoing chemotherapy
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Haematology.
Show others and affiliations
2014 (English)In: Medical Oncology, ISSN 1357-0560, E-ISSN 1559-131X, Vol. 31, no 12, 302- p.Article in journal (Refereed) Published
Abstract [en]

This randomized trial evaluated ferric carboxymaltose without erythropoiesis-stimulating agents (ESA) for correction of anemia in cancer patients with functional iron deficiency. Patients on treatment for indolent lymphoid malignancies, who had anemia [hemoglobin (Hb) 8.5-10.5 g/dL] and functional iron deficiency [transferrin saturation (TSAT) <= 20 %, ferritin >30 ng/mL (women) or >40 ng/mL (men)], were randomized to ferric carboxymaltose (1,000 mg iron) or control. Primary end point was the mean change in Hb from baseline to weeks 4, 6 and 8 without transfusions or ESA. Difficulties with patient recruitment led to premature termination of the study. Seventeen patients (8 ferric carboxymaltose and 9 control) were included in the analysis. In the ferric carboxymaltose arm, mean Hb increase was significantly higher versus control at week 8 (p = 0.021). All ferric carboxymaltose- treated patients achieved an Hb increase >1 g/dL (control 6/9; p = 0.087), and mean TSAT was >20 % from week 2 onwards. No treatment-related adverse events were reported. In conclusion, ferric carboxymaltose without ESA effectively increased Hb and iron status in this small patient population.

Place, publisher, year, edition, pages
2014. Vol. 31, no 12, 302- p.
Keyword [en]
Ferric carboxymaltose, Intravenous iron, Anemia, Lymphoid malignancies, Functional iron deficiency
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:uu:diva-238394DOI: 10.1007/s12032-014-0302-3ISI: 000344531800019PubMedID: 25373320OAI: oai:DiVA.org:uu-238394DiVA: diva2:774315
Available from: 2014-12-22 Created: 2014-12-12 Last updated: 2017-12-05Bibliographically approved

Open Access in DiVA

fulltext(252 kB)78 downloads
File information
File name FULLTEXT01.pdfFile size 252 kBChecksum SHA-512
ff89ff02dc441c501564a52bde420e11cb0a9268dd1e8b8aa01b75002223ae9c86e4d71d37ee2c5600778279b880332cdd44c9168a0effd8a2f8527147316de2
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Authority records BETA

Karlsson, TorbjörnBirgegård, Gunnar

Search in DiVA

By author/editor
Karlsson, TorbjörnBirgegård, Gunnar
By organisation
Haematology
In the same journal
Medical Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 78 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 448 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf